COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00334659
Recruitment Status : Completed
First Posted : June 8, 2006
Last Update Posted : June 23, 2011
Information provided by:

Brief Summary:
The purpose of this study is to confirm that apricitabine does not induce any clinically significant effect upon electrocardiogram (ECG) parameters at doses consistent with the maximum exposure expected to occur in clinical practice.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: apricitabine Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Double-blind, Placebo-controlled, Positive Controlled, Randomized, Crossover Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects
Study Start Date : June 2006
Actual Primary Completion Date : August 2006
Actual Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Primary Outcome Measures :
  1. QTc at individual Day 7 post-dose Tmax as determined by concurrent pharmacokinetic (PK) analysis for apricitabine [ Time Frame: day 7 ]
  2. The maximum Day 7 QTc increase from baseline observed between 1 to 4 hours post-dose, using time-matched ECG assessments [ Time Frame: day 7 ]
  3. The average Day 7 QTc observed between 1 to 4 hours post-dose [ Time Frame: day 7 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male subjects 18 - 65 years of age, inclusive.
  • Body mass index (BMI) between 18-30 kg/m2, inclusive, and a total body weight > 50 kg.
  • No clinically significant medical history.
  • No clinically significant findings on complete physical examination, including blood pressure, pulse rate and 12-lead ECG.
  • Normal clinical safety laboratory results at screening.
  • Willing and able to sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study.
  • Willing and able to stay in the clinic for the in-patient activities required by the protocol.

Exclusion Criteria:

  • Evidence of clinically relevant pathology that could interfere with the study results or put the subject's safety at risk.
  • Current or recurrent disease that may affect the action, absorption or disposition of the study treatment, or clinical or laboratory assessments.
  • Current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness, any medical disorder requiring treatment or that may make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study treatment or procedures.
  • History of febrile illness within the 5 days prior to the first dose.
  • Positive Hepatitis B surface antigen, Hepatitis C antibody or HIV test result at screening visit.
  • Use of any prescription medication within 7 days or 5 half-lives (whichever is longer) prior to the first dose of trial medication or during the study. As an exception, acetaminophen may be used at doses of ≤ 1 g/day.
  • Use of any over-the-counter (OTC) medication within 7 days or 5 half-lives (whichever is longer) prior to or during the study. Herbal supplements (including herbal weight-loss or "metabolism booster" therapies) must be discontinued 28 days prior to the first dose of trial medication.
  • Known or suspected intolerance or hypersensitivity to the study drugs, closely related compounds or any of their stated ingredients.
  • Subjects with a history of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces [150 ml] of wine, 12 ounces [360 ml] of beer or 1.5 ounces [45 ml] of hard liquor) or illicit substance abuse within 6 months of screening.
  • Positive screen for alcohol or drugs of abuse during screening visit or at study check-in.
  • History or evidence of routine use of tobacco or nicotine-containing products in excess of 5 cigarettes per day (or equivalent).
  • Participated in a clinical study involving an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study drug administration.
  • Blood donation of one pint or more within 56 days of the start of the study.
  • Plasmapheresis or plasma donation within 30 days of the start of the study.
  • Single 12-lead ECG demonstrating QTc > 450 msec at screen. A single repeat ECG may be done at the investigator's discretion.
  • Any condition that in the opinion of the investigator would complicate or compromise the study, or the well-being of the subject.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00334659

Layout table for location information
United States, Michigan
Jasper Clinic Inc.
Kalamazoo, Michigan, United States, 49007
Sponsors and Collaborators
Layout table for investigator information
Study Director: Susan W Cox, PhD Avexa

Layout table for additonal information
Responsible Party: Susan Cox, Avexa Identifier: NCT00334659    
Other Study ID Numbers: AVX-101
First Posted: June 8, 2006    Key Record Dates
Last Update Posted: June 23, 2011
Last Verified: June 2011
Keywords provided by Avexa:
HIV-1 Infection
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases